🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study

Recruitingn/aAges 18 Years - anyFemaleIstituto Oncologico Veneto IRCCS
NCT06906237 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Breast conserving surgery followed by radiotherapy is the gold standard treatment for early breast cancer. Cases with unfavorable tumor volume to breast volume ratio or challenging localizations are at higher risk of margin infiltration or poor aesthetic outcomes. While margin infiltration represents one of the strongest predictors of local recurrence, unappealing cosmetic results may significantly impair survivors' quality of life. Over the past two decades, the adoption of oncoplastic breast conserving surgery (OBCS) techniques has shown promise in improving both oncological and aesthetic outcomes after breast cancer surgery. Partial breast volume reconstruction (PBR) after OBCS is obtained through volume displacement (which involves remodelling and redistributing glandular tissue) and volume replacement (when the volume used to reconstruct the defect comes from an extramammary site) t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients treated with BCS combined with CWPFs for primary stage I-III invasive cancer (IC) or ductal carcinoma in situ (DCIS); * Patients treated during the last 10 years (2015-2025); * Patients aged 18 years or more; * Cases with at least one-year follow-up. Exclusion Criteria: * Male Patients; * Patients aged less than 18 years; * Patients who underwent traditional breast conserving surgery or OBCS with displacement techniques; * Patients who underwent mastectomy; * Patients who underwent implant-based reconstruction; * Patients with unresectable breast cancer or metastatic disease; * Patients who were lost during follow-up.
💊

What it tests

  • Not listed
📍

Where

1 site
Veneto Institute of Oncology
Padova, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy